GOSS Stock Recent News

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III PAH patients. Gossamer Bio and t.

Squarepoint Ops LLC trimmed its stake in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 51.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,944 shares of the company’s stock after selling 75,013 shares during the period. Squarepoint Ops LLC’s holdings in Gossamer Bio were worth $65,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GOSS. Two Sigma Investments LP grew its position in shares of Gossamer Bio by 41.3% in the fourth quarter. Two Sigma Investments LP now owns 891,279 shares of the company’s stock valued at $806,000 after purchasing an additional 260,318 shares during the last quarter. Two Sigma Advisers LP grew its holdings in Gossamer Bio by 44.7% in the 4th quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company’s stock valued at $1,047,000 after

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective June 5th, 2025, to three non-executive employees of non-qualified stock op.

Gossamer Bio, Inc. (NASDAQ:GOSS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard Aranda - Chief Medical Officer Caryn Peterson - EVP, Regulatory Affairs Bob Smith - Chief Commercial Officer Conference Call Participants Joseph Schwartz - SVB Leerink Andreas Argyrides - Oppenheimer Yasmeen Rahimi - Piper Sandler & Co. Paul Choi - Goldman Sachs Olivia Brayer - Cantor Patrick Trucchio - HC Wainwright Laura Chico - Wedbush Operator Good afternoon, ladies and gentlemen, and welcome to the Gossamer Bio Q1 2025 Earnings Call. I will now turn the program over to Bryan Giraudo, Chief Financial Officer and Chief Operating Officer.

Gossamer Bio (GOSS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2025, and announced the closure of new patient screening for the ongoing registrational Phase 3 PROSERA Study.

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock optio.

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 16th through 21st, in San Francisco, Califor.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective April 7, 2025, to one non-executive employee of non-qualified stock option.

Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.